Verdugo R J, Campero M, Ochoa J L
Department of Neurology, Good Samaritan Hospital, Portland, OR 97210.
Neurology. 1994 Jun;44(6):1010-4. doi: 10.1212/wnl.44.6.1010.
To test for the presence of "sympathetically maintained pain" (SMP), we administered placebo-controlled phentolamine sympathetic blocks to 14 patients with painful polyneuropathies. Six received i.v. infusion of saline for 30 minutes, followed by phentolamine (35 mg). In eight patients, the saline phase was followed by double-blind infusion of phentolamine or phenylephrine (500 micrograms), a second saline phase, and then the other active drug. We measured magnitudes of spontaneous pain and mechanical hyperalgesias on a 0-to-10 pain scale every 5 minutes and monitored sensory and sympathetic effects clinically and through quantitative thermotest and thermography. Five patients reported significant diminution of pain (> 50%), all in response to placebo. Neither phentolamine nor phenylephrine provided relief, although all patients had signs of physiologic abnormalities reputed to be determinants or predictors of SMP. These results complement previous studies demonstrating the nonexistence of SMP among "reflex sympathetic dystrophy" patients and further question the concept of SMP.
为检测“交感神经维持性疼痛”(SMP)的存在,我们对14例疼痛性多发性神经病患者进行了安慰剂对照的酚妥拉明交感神经阻滞试验。6例患者静脉输注生理盐水30分钟,随后输注酚妥拉明(35毫克)。8例患者在生理盐水输注阶段后,进行酚妥拉明或去氧肾上腺素(500微克)的双盲输注,接着是第二个生理盐水阶段,然后是另一种活性药物。我们每5分钟用0至10分疼痛量表测量自发痛和机械性痛觉过敏的程度,并通过定量温度测试和热成像技术临床监测感觉和交感神经效应。5例患者报告疼痛显著减轻(>50%),均对安慰剂有反应。尽管所有患者都有被认为是SMP的决定因素或预测指标的生理异常体征,但酚妥拉明和去氧肾上腺素均未缓解疼痛。这些结果补充了先前的研究,这些研究表明“反射性交感神经营养不良”患者中不存在SMP,并进一步质疑了SMP的概念。